argenex (NASDAQ:ARGX) was upgraded by analysts at DZ Bank AG to a "strong-buy" rating.
argenex (NASDAQ:ARGX) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
argenex (NASDAQ:ARGX) had its "neutral" rating reaffirmed by analysts at Robert W. Baird. They now have a $858.00 price target on the stock, down previously from $924.00.
argenex (NASDAQ:ARGX) had its price target raised by analysts at Royal Bank Of Canada from $860.00 to $925.00. They now have an "outperform" rating on the stock.
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease